
Senseonics Holdings (SENS) Stock Forecast & Price Target
Senseonics Holdings (SENS) Analyst Ratings
Bulls say
Senseonics Holdings Inc. is projected to experience significant revenue growth, with expectations for total revenues reaching $75.6 million in 2026 and escalating to $118.4 million in 2027, up from $59.7 million and $94.6 million, respectively. The company's gross margins are anticipated to improve beyond 50% by the end of next year, showing an increase from 43% in Q3 compared to 36% in the first half of 2025. This positive trajectory is bolstered by a remarkable 90% year-over-year growth in topline revenue and a 160% increase in new patients switching to its Eversense 365 glucose monitoring system.
Bears say
Senseonics Holdings Inc. is projecting relatively flat revenue for the first half of 2025 due to a significant conversion process affecting their U.S. operations, indicating potential stagnation in growth within a critical market. While the company's quarterly revenues slightly surpassed consensus estimates at $8.1 million, it still reported a net loss of $0.43 per share, greater than the forecasted loss of $0.40 per share, highlighting ongoing financial challenges. The reliance on international markets for revenue generation, coupled with the concerning net loss trajectory, contributes to a negative outlook on the stock despite an existing unmet demand for long-term glucose monitoring solutions.
This aggregate rating is based on analysts' research of Senseonics Holdings and is not a guaranteed prediction by Public.com or investment advice.
Senseonics Holdings (SENS) Analyst Forecast & Price Prediction
Start investing in Senseonics Holdings (SENS)
Order type
Buy in
Order amount
Est. shares
0 shares